



INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP

STUDIES COORDINATION

Oncology Institute of  
Southern Switzerland  
Ospedale San Giovanni  
CH-6500 Bellinzona  
SWITZERLAND

phone

++41 91 811 90 40

++41 91 811 91 11

fax

++41 91 811 91 82

e-mail

[ielsg@ticino.com](mailto:ielsg@ticino.com)

[www.ielsg.org](http://www.ielsg.org)

## NEWSLETTER 29

May 2008

Dear Friends,

we've just closed our 11<sup>th</sup> Annual Meeting.  
We want to thank all of you who participated and contributed to its success.

Here we want to remind you the principal issues that have been addressed and discussed either by the Board of Directors on Saturday morning and later by the IELSG General Assembly at the end of the Annual Meeting.

1.  
The most important issue is the raising concern regarding **the slow accrual** of many studies. It is evident that there are logistic and regulatory problems, which are not favoring clinical studies in a rare diseases, however **our full commitment is now needed to complete the IELSG 19** randomized study on MALT lymphomas and the **IELSG25A** phase II trial of bortezomib (the latter open in a few selected centres).
2.  
You will find enclosed a summary of the present **accrual for all the open studies** and this information will be updated and sent to all of you regularly. These data nevertheless are **continuously updated and posted in the IELSG website** where you can refer at any time for detailed information on all the ongoing and closed studies.
3.  
The Board and the Assembly have also decided to formally **close the IELSG 24** study, of intrathecal rituximab, because of the lack of accrual. The regulatory agencies will be soon informed by the Operation Office.
4.  
The Board has also reminded that all **the databases** concerning present and past studies will have to be kept **in the central office in Bellinzona**. The investigators who do not have yet sent the files will be contacted by the central office.

5.

The following **abstracts** have been accepted either for oral or poster presentation at the next **10-ICML** in **Lugano**:

“ACTIVITY OF BORTEZOMIB IN MALT LYMPHOMAS: A IELSG PHASE II STUDY”

*A. Conconi, A. Lopez-Guillermo, G. Martinelli, L. Rigacci, U. Vitolo, P. L. Zinzani, A. Ferreri, S. Luminari, M. Martelli, F. Cavalli, E. Zucca (poster)*

“RITUXIMAB IMPROVES OUTCOME IN WESTERN PATIENTS WITH INTRAVASCULAR LARGE B-CELL LYMPHOMA (IVL)”

*G. P. Dognini, M. Ponzoni, O. Bairey, C. Montalbàn, A. Szomor, L. Uziel, J. Seymour, A. Ambrosetti, M. Martelli, G. Rossi, M. Federico, A. Candoni, A. De Renzo, M. Piris, E. Zucca, C. Doglioni, A. J. Ferreri on behalf of the International Extranodal Lymphoma Study Group (poster)*

“INTRAVASCULAR LARGE B-CELL LYMPHOMA(IVLBCL): INTERNATIONAL CONSENSUS ON DIAGNOSTIC AND THERAPEUTIC ISSUES”

*M. Ponzoni, A. J. Ferreri, E. Campo, G. P. Dognini, F. Facchetti, T. Kinoshita, L. Mazzucchelli, T. Yoshino, T. Murase, M. Seto, K. Shimada, S. A. Pileri, C. Doglioni, E. Zucca, F. Cavalli, S. Nakamura, on Behalf of International Intravascular Lymphoma Study Group (poster)*

“RITUXIMAB(R) CHOP WITH CNS AND CONTRALATERAL TESTIS PROPHYLAXIS IMPROVES THE OUTCOME OF PRIMARY TESTICULAR LYMPHOMA(PTL): FINAL RESULTS OF IELSG10 STUDY”

*U. Vitolo, E. Zucca, A. Chiappella, M. Balzarotti, C. Bottelli, A. Conconi, P. De Masi, H. Gomez, A. Lopez-Guillermo, M. Martelli, G. Martinelli, F. Merli, V. Naso, L. Orsucci, V. Pavone, V. Secondo, S. Storti, M. Gospodarowicz, A. Sarris, F. Cavalli, on behalf of International Extranodal Lymphoma Study Group (oral)*

“RANDOMIZED PHASE II TRIAL ON PRIMARY CHEMOTHERAPY (CHT) WITH HIGH-DOSE METHOTREXATE (MTX) ALONE OR ASSOCIATED WITH HIGH-DOSE CYTARABINE (ARAC) FOR PATIENTS (PTS) WITH PRIMARY CNS LYMPHOMA (PCNSL)”

*A. J. Ferreri, M. Foppoli, M. Martelli, G. Pangalis, M. Frezzato, G. Cabras, A. Fabbri, G. Corazzelli, F. Ilariucci, G. Rossi, R. Soffietti, C. Stelitano, D. Vallisa, F. Zaja, L. Zoppegno, G. Aondio, O. Annibali, M. Balzarotti, A. Brandes, J. Fajardo, H. Gomez, A. Guarini, G. Pinotti, L. Rigacci, C. Uhlmann, M. Ponzoni, M. Reni, E. Zucca, F. Cavalli. International Extranodal Lymphoma Study Group (IELSG), Switzerland (oral)*

During the **13<sup>th</sup> congress of the European Hematology Association (EHA)** in Copenhagen next month of June, abstracts concerning IELSG studies will be presented as well:

“PRIMARY EXTRANODAL FOLLICULAR LYMPHOMA OF HEAD AND NECK (PEFLHN): A RARE DISEASE WITH A POOR CLINICAL OUTCOME (IELSG 23)”

*Cortelazzo S., Mian M., Tsang R., Rossi A., Cabrera M.E., Federico M., Zucca E., Busetto M., Rambaldi A., and Cavalli F., on behalf of IELSG and IIL (poster)*

“RANDOMIZED PHASE II TRIAL ON PRIMARY CHEMOTHERAPY (CHT) WITH HIGH-DOSE METHOTREXATE (MTX) ALONE OR ASSOCIATED WITH HIGH-DOSE CYTARABINE (ARAC) FOR PATIENTS (PTS) WITH PRIMARY CNS LYMPHOMA (PCNSL)”

*Ferreri A.J., Foppoli M., Martelli M., Pangalis G., Frezzato M., Cabras G., Fabbri A., Corazzelli G., Ilariucci F., Rossi G., Soffietti R., Stelitano C., Vallisa D., Zaja F., Zoppegno L., Aondio G., Annibali O., Balzarotti M., Brandes A., Fajardo J., Gómez H., Guarini A., Pinotti G., Rigacci L., Uhlmann C., Ponzoni M., Reni M., Zucca E., Cavalli F. on behalf of the International Extranodal Lymphoma Study Group (oral)*

“PRIMARY DIFFUSE LARGE B-CELL LYMPHOMA OF THE TESTIS: IMPROVED OUTCOME WITH RITUXIMAB-CHOP WITH CNS AND CONTRALATERAL TESTIS PROPHYLAXIS. FINAL RESULTS OF IELSG 10 STUDY”

*U. Vitolo, E. Zucca, M. Martelli, A. Chiappella, M. Balzarotti, G. Benevolo, P. De Masi, A. Filippi, M.K. Gospodarowicz, A. Lopez-Guillermo, G. Martinelli, F. Merli, T. Perrone, P. Pregno, A.H. Sarris, S. Storti and F. Cavalli on the behalf of IELSG and IIL (oral)*

We congratulate the authors and again thank the IELSG investigators for their commitment.

6.

**Details on the ongoing** studies have been included in the **proceedings** of the meeting, which are available upon request to the [ielsg@ticino.com](mailto:ielsg@ticino.com).

7.

The **next studies to be opened** will comprise the phase II clinical trials on the treatment of **testis lymphomas** and the primary **CNS lymphomas** as well as prospective collection of clinical information on the treatment of **breast lymphoma** and **intravascular lymphoma**. The protocols are in preparation and further relevant information will be posted on the website. With respect to the ongoing studies however you will find already attached the **protocols** and **forms** for participating to the **retrospective survey on primary extranodal follicular lymphomas** (IELSG 31).

Again thanks to all of you and also thanks to Markus Manz (Bellinzona, Switzerland) and Ian Magrath (Brussels, Belgium) for their outstanding educational lectures.

Best wishes,

*F. Cavalli, E. Zucca, A. Conconi, C. Morinini, M. Bertini, E. Porro*